These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17725429)

  • 1. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
    Meireles AM; Preto A; Rocha AS; Rebocho AP; Máximo V; Pereira-Castro I; Moreira S; Feijão T; Botelho T; Marques R; Trovisco V; Cirnes L; Alves C; Velho S; Soares P; Sobrinho-Simões M
    Thyroid; 2007 Aug; 17(8):707-15. PubMed ID: 17725429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
    Di Cristofaro J; Marcy M; Vasko V; Sebag F; Fakhry N; Wynford-Thomas D; De Micco C
    Hum Pathol; 2006 Jul; 37(7):824-30. PubMed ID: 16784981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
    Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fine-needle aspiration cytology of thyroid nodules: molecular diagnostics in a routine diagnostic setting].
    Eszlinger M; Neustadt M; Ruschenburg I; Neumann A; Franzius C; Adam S; Bacher K; Hach A; Hammoser R; Langvogt C; Molwitz T; Paschke R
    Dtsch Med Wochenschr; 2014 Mar; 139(10):476-80. PubMed ID: 24570192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
    Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
    Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas.
    Pallante P; Visone R; Croce CM; Fusco A
    Endocr Relat Cancer; 2010 Mar; 17(1):F91-104. PubMed ID: 19942715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.
    Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
    J Pathol; 2008 May; 215(1):87-96. PubMed ID: 18306168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma.
    Anania MC; Miranda C; Vizioli MG; Mazzoni M; Cleris L; Pagliardini S; Manenti G; Borrello MG; Pierotti MA; Greco A
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1591-600. PubMed ID: 23928665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.
    Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E
    Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
    Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
    Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.
    Pilli T; Prasad KV; Jayarama S; Pacini F; Prabhakar BS
    Thyroid; 2009 Dec; 19(12):1333-42. PubMed ID: 20001716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.